[1]王宇秀,杨永生,石嘉颖,等.基于OPG/RANK/RANKL信号通路研究补肾强督方对大鼠去卵巢骨质疏松的作用机制[J].陕西中医,2024,(10):1330-1335.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.007]
　WANG Yuxiu,YANG Yongsheng,SHI Jiaying,et al.Study on Bushen Qiangdu formula based on OPG/RANK/RANKL signaling pathway mechanism of action on ovariectomized osteoporosis rats[J].,2024,(10):1330-1335.[doi:DOI:10.3969/j.issn.1000-7369.2024.10.007]
点击复制

基于OPG/RANK/RANKL信号通路研究补肾强督方对大鼠去卵巢骨质疏松的作用机制
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2024年10期
页码:
1330-1335
栏目:
基础研究
出版日期:
2024-10-05

文章信息/Info

Title:
Study on Bushen Qiangdu formula based on OPG/RANK/RANKL signaling pathway mechanism of action on ovariectomized osteoporosis rats
作者:
王宇秀1; 杨永生2; 石嘉颖3; 吴 昊3
(1.内蒙古自治区第四医院,内蒙古 呼和浩特 010051; 2.呼和浩特市蒙医中医医院,内蒙古 呼和浩特 010050; 3.内蒙古医科大学,内蒙古 呼和浩特 010107)
Author(s):
WANG Yuxiu; YANG Yongsheng; SHI Jiaying; WU Hao
(Inner Mongolia Fourth Hospital,Hohhot 010051,China)
关键词:
骨质疏松;  补肾强督方;  骨保护素;  核因子κB受体活化因子配体;  核因子κB受体活化因子;  肿瘤坏死因子受体相关因子6
Keywords:
Osteoporosis;  Bushen Qiangdu prescription;  Osteoprotegerin;  Receptor activator of nuclear factor-κB ligand;  Receptor activator of nuclear factor-κB;  Tumor necrosis factor receptor-associated factor 6
分类号:
R 681
DOI:
DOI:10.3969/j.issn.1000-7369.2024.10.007
文献标志码:
A
摘要:
目的:观察补肾强督方干预去卵巢所致骨质疏松(OP)大鼠对OPG/RANK/RANKL信号通路的影响,以探索补肾强督方防治绝经后骨质疏松(PMOP)的机制。方法:选取40只SPF级雌性SD大鼠适应性喂养1周后称重并按照体重大小从低到高依次编号,然后利用随机数字表法分为假手术组(6只)和手术组(34只),手术组中有4只因为手术原因死亡,剩余30只,手术组切除双侧卵巢构建OP大鼠模型后分为模型对照组、阿仑膦酸钠组、补肾强督方高剂量组、补肾强督方中剂量组、补肾强督方低剂量组各6只。假手术组仅切除等重量卵巢旁脂肪组织。药物干预10周后取大鼠左右股骨及腹主动脉采血制备血清,采用酶联免疫吸附法(ELISA)检测血清中核因子κB受体活化因子(RANK)、核因子κB受体活化因子配体(RANKL)、骨保护素(OPG)、肿瘤坏死因子受体相关因子6(TRAF6)、骨钙素(OCN)水平情况,分别采用蛋白质免疫印迹法(Western blot)和实时荧光定量聚合酶链式反应法(RT-PCR)检测骨组织OPG、RANK、RANKL蛋白及mRNA的表达,并进行统计学处理。结果:补肾强督方可以促进血清中OPG含量以及股骨中OPG蛋白及mRNA的表达,抑制血清中RANK、RANKL、TRAF6、OCN含量和股骨中RANK、RANKL蛋白及mRNA的表达。结论:补肾强督方可能通过调控OPG/RANKL/RANK信号通路以及下游TRAF6因子的表达抑制破骨细胞增殖、刺激成骨细胞的表达,动态调节骨代谢的平衡。
Abstract:
Objective:To observe the effect of Bushen Qiangdu decoction on OPG/RANKL/RANK signaling pathway in ovariectomized osteoporosis(OP)rats,and to explore the mechanism of Bushen Qiangdu decoction in the prevention and treatment of postmenopausal osteoporosis(PMOP).Methods:A total of 40 SPF female SD rats were selected after adaptive feeding for 1 week and weighed and numbered according to the weight from low to high.Then they were divided into sham operation group(6 rats)and operation group(34 rats)by random number method.After the bilateral ovaries of the operation group were removed to construct the OP rat model,they were divided into model control group,alendronate sodium group,high dose group of Bushen Qiangdu decoction,middle dose group of Bushen Qiangdu decoction and low dose group of Bushen Qiangdu decoction.The sham operation group only removed the same weight of paraovarian adipose tissue.After 10 weeks of drug intervention,blood samples were collected from the left and right femurs and abdominal aortas of rats to prepare serum.The levels of receptor activator of nuclear factor-κB(RANK),receptor activator of nuclear factor-κB ligand(RANKL),osteoprotegerin(OPG),tumor necrosis factor receptor-associated factor 6(TRAF6)and osteocalcin(OCN)in serum were detected by enzyme-linked immunosorbent assay(ELISA).The expression of OPG,RANK and RANKL protein and mRNA in bone tissue were detected by Western blot and real-time fluorescence quantitative polymerase chain reaction(RT-PCR),and statistical analysis was performed.Results:Bushen Qiangdu decoction can promote the expression of OPG in serum and OPG protein and mRNA in femur,inhibit the expression of RANK,RANKL,TRAF6,OCN in serum and RANK,RANKL protein and mRNA in femur.Conclusion:Bushen Qiangdu decoction may inhibit the proliferation of osteoclasts and stimulate the expression of osteoblasts by regulating the RANK/RANKL/OPG signaling pathway and the expression of downstream TRAF6 factors,and dynamically regulate the balance of bone metabolism.

参考文献/References:

[1] CAULEY J A.Osteoporosis:Fracture epidemiology update 2016[J].Curr Opin Rheumatol,2017,29(2):150-156.
[2] 中华医学会骨质疏松和骨矿盐疾病分会.中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(4):317-318.
[3] 王健,廖燚,袁锋.骨代谢标志物在骨质疏松中的应用进展[J].河北医药,2021,43(20):3164-3170.
[4] YASUDA H.Discovery of the RANKL/RANK/OPG system[J].Journal of Bone and Mineral Metabolism,2021,39(1):2-11.
[5] 邱新萍,孙颂歌,张辰.补肾强督方对肾虚督寒型骨质疏松症患者骨密度影响的临床研究[J].中医临床研究,2021,13(3):101-102,119.
[6] 李素萍.骨质疏松动物模型的研究现状[J].中国组织工程研究与临床康复,2011,15(20):3767-3770.
[7] 李洺,赵宇,马丁,等.女性绝经后骨质疏松症患者血清铁蛋白、同源拮抗物表达水平及临床意义[J].陕西医学杂志,2020,49(10):1266-1269.
[8] LEE N H,KANG M S,KIM T H,et al.Dual actions of osteoclastic-inhibition and osteogenic-stimulation through strontium-releasing bioactive nanoscale cement imply biomaterial-enabled osteoporosis therapy[J].Biomaterials,2021,276:121025.
[9] JANG S A,HWANG Y H,YANG H,et al.Water extract of mentha arvensis attenuates estrogen deficiency-induced bone loss by inhibiting osteoclast differentiation[J].Front Pharmacol,2021,12:719602.
[10] 陈铭,徐道明,朱璐,等.基于《黄帝内经》浅析骨质疏松症的论治[J].中国骨质疏松杂志,2020,26(5):727-730.
[11] 周大标,吴冰心,阳越,等.基于肝脾肾探讨绝经后骨质疏松症治疗机制[J].陕西中医,2022,43(6):752-754,766.
[12] 陈巨鹏,严晓莺,黄国淳,等.从燮理肝脾肾治疗绝经后骨质疏松症探讨[J].陕西中医,2020,41(11):1635-1638.
[13] 王建明.补肾强督方治疗强直性脊柱炎患者的临床研究及机制探讨[D].北京:北京中医药大学,2005.
[14] 胡思婧,练晨霞,张奇,等.熟地黄的大麻素2型受体激动剂活性及对骨代谢的调控作用研究[J].中草药,2022,53(20):6481-6491.
[15] 张峻玮,李琰,薛海鹏,等.骨碎补经骨髓间充质干细胞调节OPG/RANKL/RANK通路抑制破骨细胞的实验研究[J].中国骨质疏松杂志,2019,25(5):617-624.
[16] 尚延春,张海英,柴巍巍.异补骨脂素改善骨质疏松大鼠骨代谢的作用探讨[J].中国骨质疏松杂志,2021,27(2):220-224.
[17] 郑寅涛,曹岗,吴鑫.山茱萸-白芍酒炙配伍前后通过调节OPG/RANKL/RANK信号通路抗类风湿性关节炎药效机制研究[J].中草药,2022,53(10):3084-3092.
[18] 徐愿,阎小萍,张文健.补肾强督方含药血清对强直性脊柱炎OPG/RANKL通路的作用[J].中国中西医结合杂志,2012,32(4):521-524.
[19] ERBEN R G.Hypothesis:Coupling between resorption and formation in cancellous bone remodeling is a mechanically controlled event[J].Front E Ndocrinol(Lausanne),2015,6(5):82.
[20] ZHANG S,LI X,QI Y,et al.Comparison of autogenous tooth materials and other bone grafts[J].Tissue Eng Regen Med,2021,18(3):327-341.
[21] 张萌萌,马倩倩,毛未贤.骨代谢生化指标临床应用专家共识(2023修订版)[J].中国骨质疏松杂志,2023,29(4):469-476.
[22] 中华医学会骨质疏松和骨矿盐疾病分会,章振林.原发性骨质疏松症诊疗指南(2022)[J].中国全科医学,2023,26(14):1671-1691.
[23] 卜寒梅,王世坤,李远栋,等.补肾中药基于OPG/RANKL/RANK信号通路对原发性骨质疏松症作用机制的研究进展[J].中草药,2022,53(10):3209-3217.
[24] CAVEY J R,RALSTON S H,SHEPPARD P W,et al.Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone[J].Calcified Tissue International,2006,78(5):271-277.
[25] 曹闲雅.基于TRAF6、TAK1的表达探讨金刚丸对肾阳虚型PMOP大鼠的影响[D].长沙:湖南中医药大学,2021.
[26] CHI P J,HUNG S Y,HSIAO F T,et al.Serum osteocalcin concentration as an independent biomarker of osteoporosis in patients with chronic kidney disease[J].Clin Nephrol,2022,98(1):1-9.
[27] JIA L,CHENG M.Correlation analysis between risk factors,BMD and serum osteocalcin,CatheK,PINP,β-crosslaps,TRAP,lipid metabolism and BMI in 128 patients with postmenopausal osteoporotic fractures[J].European Review for Medical and Pharmacological Sciences,2022,26(21):7955-7959.

相似文献/References:

[1]贾 辉.利塞膦酸钠联合中药对老年女性髋骨骨折的影响研究*[J].陕西中医,2019,(2):226.
[2]李鸿,徐无忌△.加味身痛逐瘀汤治疗骨质疏松椎体压缩性骨折经皮穿刺椎体成形术后残余痛临床研究*[J].陕西中医,2019,(11):1545.
　LI Hong,XU Wuji..Clinical observation on residual pain after PVP in the treatment of osteoporotic vertebral compression fracture with Jiawei Shentong Zhuyu decoction[J].,2019,(10):1545.
[3]杨庆万,安 阳△,项飞燕,等.引火汤对类风湿关节炎患者骨代谢的影响*[J].陕西中医,2020,(1):73.
　YANG Qingwan,AN Yang,XIANG Feiyan,et al.Effect of Yinhuo decoction on bone metabolism in patients with rheumatoid arthritis[J].,2020,(10):73.
[4]刘志刚,秦 琳,张挥武△.温针灸联合经皮椎体后凸成形术治疗骨质疏松性椎体压缩性骨折疗效及对患者骨密度和血钙的影响*[J].陕西中医,2020,(6):823.[doi:DOI:10.3969/j.issn.10007369.2020.06.035]
　LIU Zhigang,QIN Lin,ZHANG Huiwu..Efficacy of warm acupuncture combined with percutaneous kyphoplasty in treating of osteoporotic vertebral compression fracture and the effect on BMD and serum calcium level[J].,2020,(10):823.[doi:DOI:10.3969/j.issn.10007369.2020.06.035]
[5]申杨勇,陈京峰,崇 辉.四神煎加减联合青鹏软膏对骨质疏松性胸腰椎压缩性骨折患者术后疼痛及骨折愈合的影响[J].陕西中医,2020,(12):1719.[doi:DOI:10.3969/j.issn.1000-7369.2020.12.010]
[6]张 宁,董一平,袁 强,等.中医药通过作用破骨细胞调控治疗绝经后骨质疏松研究进展[J].陕西中医,2024,(1):136.[doi:DOI:10.3969/j.issn.1000-7369.2024.01.032]
　ZHANG Ning,DONG Yiping,YUAN Qiang,et al.Advances in the treatment of postmenopausal osteoporosis by Chinese medicine using osteoclasts[J].,2024,(10):136.[doi:DOI:10.3969/j.issn.1000-7369.2024.01.032]
[7]张民珍,罗 文,杨黎艳,等.巴戟天多糖对大鼠骨质疏松的作用机制研究[J].陕西中医,2024,(3):302.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.003]
　ZHANG Minzhen,LUO Wen,YANG Liyan,et al.Study on mechanism of Morinda polysaccharide on osteoporosis in rats[J].,2024,(10):302.[doi:DOI:10.3969/j.issn.1000-7369.2024.03.003]
[8]姜凤依,施 丹,季思勤,等.补肾健脾通络方结合五行健骨操对老年骨质疏松脾肾两虚证患者骨密度、骨代谢及炎症水平的影响[J].陕西中医,2024,(4):485.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.011]
　JIANG Fengyi,SHI Dan,JI Siqin,et al.Effects of Bushen Jianpi Tongluo formula combined with five elements bone-building exercises on bone mineral density,bone metabolism and inflammation in elderly patients with spleen-kidney deficiency syndrome of osteoporosis[J].,2024,(10):485.[doi:DOI:10.3969/j.issn.1000-7369.2024.04.011]

备注/Memo

备注/Memo:
基金项目:内蒙古自治区科技计划项目(2021GG0186); 第五批全国中医临床优秀人才研修项目[国中医药人教函(2022)1号]
更新日期/Last Update: 2024-10-08